Bioinformatics and Systems Biology Approach to Identify the Pathogenetic Link Between Psoriasis and Cardiovascular Disease

References

• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Lai YC, Yew YW. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. J Cutan Med Surg. 2016;20(4):327–333. doi:10.1177/1203475415602842
   PubMed Web of Science ®Google Scholar
• Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–67. doi:10.1111/j.0022-202X.2005.23681.x
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi:10.1007/s00403-006-0703-z
   PubMed Web of Science ®Google Scholar
• Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68–73. doi:10.1111/j.1365-2133.2007.07986.x
   PubMed Web of Science ®Google Scholar
• Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211. doi:10.3390/ijms18102211
   PubMed Web of Science ®Google Scholar
• Shih CM, Chen CC, Chu CK, Wang KH, Huang CY, Lee AW. The roles of lipoprotein in psoriasis. Int J Mol Sci. 2020;21(3):859. doi:10.3390/ijms21030859
   PubMed Web of Science ®Google Scholar
• Egeberg A, Thyssen JP, Jensen P, Gislason GH, Skov L. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. Acta Derm Venereol. 2017;97(7):819–824. doi:10.2340/00015555-2657
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi:10.1001/jama.296.14.1735
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol. 2012;109(7):976–980. doi:10.1016/j.amjcard.2011.11.025
   PubMedGoogle Scholar
• Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol. 2012;166(4):811–818. doi:10.1111/j.1365-2133.2011.10774.x
   PubMed Web of Science ®Google Scholar
• Liu L, Cui S, Liu M, Huo X, Zhang G, Wang N. Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and meta-analysis of cohort study. Front Cardiovasc Med. 2022;9:829709. doi:10.3389/fcvm.2022.829709
   PubMed Web of Science ®Google Scholar
• Sajja AP, Joshi AA, Teague HL, Dey AK, Mehta NN. Potential immunological links between psoriasis and cardiovascular disease. Front Immunol. 2018;9:1234. doi:10.3389/fimmu.2018.01234
   PubMed Web of Science ®Google Scholar
• Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345–352. doi:10.1016/j.jaad.2018.02.040
   PubMed Web of Science ®Google Scholar
• von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096. doi:10.3389/fimmu.2019.03096
   PubMed Web of Science ®Google Scholar
• Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19(1):58. doi:10.3390/ijms19010058
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–157. doi:10.1111/j.1365-2796.2010.02310.x
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161(1):1–7. doi:10.1111/j.1365-2133.2009.09281.x
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139(5):1054–1062. doi:10.1016/j.jid.2018.10.042
   PubMed Web of Science ®Google Scholar
• Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–728. doi:10.1093/cvr/cvz009
   PubMed Web of Science ®Google Scholar
• Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol. 2018;70(3):408–416. doi:10.1002/art.40366
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi:10.1056/NEJMra0804595
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. J Dermatol. 2021;48(6):722–731. doi:10.1111/1346-8138.15913
   PubMed Web of Science ®Google Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33(1):13–23. doi:10.1016/j.det.2014.09.002
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7
   PubMed Web of Science ®Google Scholar
• Wu J, Saleh MA, Kirabo A, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016;126(1):50–67. doi:10.1172/JCI80761
   PubMed Web of Science ®Google Scholar
• Huang LH, Zinselmeyer BH, Chang CH, et al. Interleukin-17 drives interstitial entrapment of tissue lipoproteins in experimental psoriasis. Cell Metab. 2019;29(2):475–487.e477. doi:10.1016/j.cmet.2018.10.006
   PubMed Web of Science ®Google Scholar
• Chen M, Ma L, Hall JE, Liu X, Ying Z. Dual regulation of tumor necrosis factor-α on myosin light chain phosphorylation in vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2015;308(5):H398–H406. doi:10.1152/ajpheart.00691.2014
   PubMed Web of Science ®Google Scholar
• Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73(1):205–209. doi:10.1161/01.RES.73.1.205
   PubMed Web of Science ®Google Scholar
• Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci. 2009;116(3):219–230. doi:10.1042/CS20080196
   PubMed Web of Science ®Google Scholar
• Piaserico S, Osto E, Famoso G, et al. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis. 2016;251:25–30. doi:10.1016/j.atherosclerosis.2016.05.036
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. doi:10.1001/2013.jamadermatol.406
   PubMed Web of Science ®Google Scholar
• Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–1796. doi:10.1038/jid.2010.103
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–476. doi:10.1038/nrd4275
   PubMed Web of Science ®Google Scholar
• Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. Keratinocytes in inflammatory skin diseases. Curr Drug Targets Inflamm Allergy. 2005;4(3):329–334. doi:10.2174/1568010054022033
   PubMedGoogle Scholar
• Gillitzer R, Wolff K, Tong D, et al. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol. 1993;101(2):127–131. doi:10.1111/1523-1747.ep12363613
   PubMed Web of Science ®Google Scholar
• Hedayati-Moghadam M, Hosseinian S, Paseban M, et al. The role of chemokines in cardiovascular diseases and the therapeutic effect of curcumin on CXCL8 and CCL2 as pathological chemokines in atherosclerosis. Adv Exp Med Biol. 2021;1328:155–170.
   PubMedGoogle Scholar
• Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170(6):3369–3376. doi:10.4049/jimmunol.170.6.3369
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Peters RJ, Hack CE, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2004;24(8):1503–1508. doi:10.1161/01.ATV.0000134294.54422.2e
   PubMed Web of Science ®Google Scholar
• Martynowicz H, Janus A, Nowacki D, Mazur G. The role of chemokines in hypertension. Adv Clin Exp Med. 2014;23(3):319–325. doi:10.17219/acem/37123
   PubMed Web of Science ®Google Scholar
• Ganjali S, Sahebkar A, Mahdipour E, et al. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial. ScientificWorldJournal. 2014;2014:898361. doi:10.1155/2014/898361
   PubMed Web of Science ®Google Scholar
• Aukrust P, Berge RK, Ueland T, et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol. 2001;37(2):485–491. doi:10.1016/S0735-1097(00)01110-4
   PubMed Web of Science ®Google Scholar
• Jaiswal AK, Sadasivam M, Archer NK, et al. Syndecan-1 regulates psoriasiform dermatitis by controlling homeostasis of IL-17-producing γδ T cells. J Immunol. 2018;201(6):1651–1661. doi:10.4049/jimmunol.1800104
   PubMed Web of Science ®Google Scholar
• Starodubtseva NL, Sobolev VV, Soboleva AG, Nikolaev AA, Bruskin SA. [Expression of genes for metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis]. Genetika. 2011;47(9):1254–1261. Russian.
   PubMedGoogle Scholar
• Wagner M, Theodoro TR, Filho C, Oyafuso LKM, Pinhal MAS. Extracellular matrix alterations in the skin of patients affected by psoriasis. BMC Mol Cell Biol. 2021;22(1):55. doi:10.1186/s12860-021-00395-1
   PubMed Web of Science ®Google Scholar
• Hopps E, Caimi G. Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci. 2015;19(14):2583–2589.
   PubMed Web of Science ®Google Scholar
• Mirhafez SR, Avan A, Tajfard M, et al. Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease. J Clin Lab Anal. 2017;31(5):e22100. doi:10.1002/jcla.22100
   PubMed Web of Science ®Google Scholar
• El-Aziz TAA, Mohamed RH. Matrix metalloproteinase −9 polymorphism and outcome after acute myocardial infarction. Int J Cardiol. 2017;227:524–528. doi:10.1016/j.ijcard.2016.10.109
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Tousoulis D, Papageorgiou N, et al. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease. Curr Top Med Chem. 2012;12(10):1214–1221. doi:10.2174/1568026611208011214
   PubMed Web of Science ®Google Scholar
• Cai H, Ma Y, Jiang L, et al. Hypoxia response element-regulated MMP-9 promotes neurological recovery via glial scar degradation and angiogenesis in delayed stroke. Mol Ther. 2017;25(6):1448–1459. doi:10.1016/j.ymthe.2017.03.020
   PubMed Web of Science ®Google Scholar
• Rathnayake N, Gustafsson A, Norhammar A, et al. Salivary matrix metalloproteinase-8 and -9 and myeloperoxidase in relation to coronary heart and periodontal diseases: a subgroup report from the PAROKRANK Study (Periodontitis and its relation to coronary artery disease). PLoS One. 2015;10(7):e0126370. doi:10.1371/journal.pone.0126370
   PubMed Web of Science ®Google Scholar
• Buerger C, Richter B, Woth K, et al. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol. 2012;132(9):2206–2214. doi:10.1038/jid.2012.123
   PubMed Web of Science ®Google Scholar
• Epelman S, Lavine KJ, Beaudin AE, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity. 2014;40(1):91–104. doi:10.1016/j.immuni.2013.11.019
   PubMed Web of Science ®Google Scholar
• Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci. 2018;132(12):1243–1252. doi:10.1042/CS20180306
   PubMed Web of Science ®Google Scholar
• Zhu Y, Xian X, Wang Z, et al. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules. 2018;8(3):80. doi:10.3390/biom8030080
   PubMed Web of Science ®Google Scholar
• Ain QU, Sarfraz M, Prasesti GK, Dewi TI, Kurniati NF. Confounders in identification and analysis of inflammatory biomarkers in cardiovascular diseases. Biomolecules. 2021;11(10):1464. doi:10.3390/biom11101464
   PubMed Web of Science ®Google Scholar
• Deng J, Tan S, Liu R, et al. Chinese medicine formula PSORI-CM02 alleviates psoriatic dermatitis via M-MDSCs and Th17 crosstalk. Front Pharmacol. 2020;11:563433. doi:10.3389/fphar.2020.563433
   PubMed Web of Science ®Google Scholar
• Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis. 2016;6:7–32. doi:10.2147/PTT.S64950
   PubMedGoogle Scholar
• Bruch-Gerharz D, Schnorr O, Suschek C, et al. Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. Am J Pathol. 2003;162(1):203–211. doi:10.1016/S0002-9440(10)63811-4
   PubMed Web of Science ®Google Scholar
• Zhu M, Goetsch SC, Wang Z, et al. FoxO4 promotes early inflammatory response upon myocardial infarction via endothelial Arg1. Circ Res. 2015;117(11):967–977. doi:10.1161/CIRCRESAHA.115.306919
   PubMed Web of Science ®Google Scholar
• Shiraishi M, Shintani Y, Shintani Y, et al. Alternatively activated macrophages determine repair of the infarcted adult murine heart. J Clin Invest. 2016;126(6):2151–2166. doi:10.1172/JCI85782
   PubMed Web of Science ®Google Scholar
• Korkmaz S, Korkmaz H. Effect of alterations in apoptotic pathway on development of metabolic syndrome in patients with psoriasis vulgaris. Br J Dermatol. 2017;176(6):1549–1557. doi:10.1111/bjd.15185
   PubMed Web of Science ®Google Scholar
• Liu Y, Shang G, Zhang X, et al. CAMTA1 gene affects the ischemia-reperfusion injury by regulating CCND1. Front Cell Neurosci. 2022;16:868291. doi:10.3389/fncel.2022.868291
   PubMed Web of Science ®Google Scholar
• Calautti E, Avalle L, Poli V. Psoriasis: a STAT3-centric view. Int J Mol Sci. 2018;19(1):171. doi:10.3390/ijms19010171
   PubMed Web of Science ®Google Scholar
• Wang A, Wei J, Lu C, et al. Genistein suppresses psoriasis-related inflammation through a STAT3-NF-κB-dependent mechanism in keratinocytes. Int Immunopharmacol. 2019;69:270–278. doi:10.1016/j.intimp.2019.01.054
   PubMed Web of Science ®Google Scholar
• Dutzmann J, Daniel JM, Bauersachs J, Hilfiker-Kleiner D, Sedding DG. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res. 2015;106(3):365–374. doi:10.1093/cvr/cvv103
   PubMed Web of Science ®Google Scholar
• Zgraggen S, Huggenberger R, Kerl K, Detmar M, Ribatti D. An important role of the SDF-1/CXCR4 axis in chronic skin inflammation. PLoS One. 2014;9(4):e93665. doi:10.1371/journal.pone.0093665
   PubMed Web of Science ®Google Scholar
• Petzold T, Zhang Z, Ballesteros I, et al. Neutrophil “plucking” on megakaryocytes drives platelet production and boosts cardiovascular disease. Immunity. 2022;55(12):2285–2299.e2287. doi:10.1016/j.immuni.2022.10.001
   PubMed Web of Science ®Google Scholar
• Rubin AJ, Barajas BC, Furlan-Magaril M, et al. Lineage-specific dynamic and pre-established enhancer-promoter contacts cooperate in terminal differentiation. Nat Genet. 2017;49(10):1522–1528. doi:10.1038/ng.3935
   PubMed Web of Science ®Google Scholar
• Bin L, Deng L, Yang H, et al. Forkhead box C1 regulates human primary keratinocyte terminal differentiation. PLoS One. 2016;11(12):e0167392. doi:10.1371/journal.pone.0167392
   PubMed Web of Science ®Google Scholar
• Zeng F, Liu H, Lu D, Liu Q, Chen H, Zheng F. Integrated analysis of gene expression profiles identifies transcription factors potentially involved in psoriasis pathogenesis. J Cell Biochem. 2019;120(8):12582–12594. doi:10.1002/jcb.28525
   PubMed Web of Science ®Google Scholar
• Kume T, Jiang H, Topczewska JM, Hogan BL. The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev. 2001;15(18):2470–2482. doi:10.1101/gad.907301
   PubMed Web of Science ®Google Scholar
• Seo S, Fujita H, Nakano A, Kang M, Duarte A, Kume T. The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev Biol. 2006;294(2):458–470. doi:10.1016/j.ydbio.2006.03.035
   PubMed Web of Science ®Google Scholar